ruxolitinib – Medxy AI

Topical Janus Kinase Inhibition in Hidradenitis Suppurativa: A New Frontier for Mild-to-Moderate Disease

By MedXY 03/05/2026

A Phase 2 RCT demonstrates that ruxolitinib 1.5% cream significantly reduces inflammatory lesion counts in mild-to-moderate hidradenitis suppurativa with a favorable safety profile, addressing a critical therapeutic gap for Hurley stage I and II patients.

$Ruxolitinib Improves Failure-Free and Overall Survival Versus Best Available Therapy in Steroid-Refractory Acute GVHD: Final 24‑Month REACH2 Analysis$

Hematology-Oncology news Transplantation

Ruxolitinib Improves Failure-Free and Overall Survival Versus Best Available Therapy in Steroid-Refractory Acute GVHD: Final 24‑Month REACH2 Analysis

By MedXY 12/09/2025

The 24‑month final analysis of the phase III REACH2 trial shows ruxolitinib produced longer failure‑free survival, improved median overall and event‑free survival, and a longer duration of response versus best available therapy (BAT) in patients with steroid‑refractory acute GVHD.

$Ruxolitinib Offers Durable Clinical Benefit in Steroid-Refractory Chronic Graft-Versus-Host Disease: Three-Year Final Results of the REACH3 Trial$

Clinical Updates news Specialties Transplantation

Ruxolitinib Offers Durable Clinical Benefit in Steroid-Refractory Chronic Graft-Versus-Host Disease: Three-Year Final Results of the REACH3 Trial

By MedXY 08/07/2025

The REACH3 study confirms ruxolitinib's superiority over best available therapy in steroid-refractory/dependent chronic GVHD, demonstrating sustained efficacy, improved failure-free survival, and a manageable long-term safety profile over three years.